Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate is a crystalline solid form of the clinically validated ACE inhibitor lisinopril (IC50 = 4.7 nM), enabling selective blockade of angiotensin converting enzyme in vitro and in vivo (Tieku & Hooper 1992). It acts by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone levels. This compound is highly water-soluble (≥2.46 mg/mL, with gentle warming and ultrasonic treatment) and is ≥98% pure per APExBIO’s Certificate of Analysis. Lisinopril dihydrate is widely used in preclinical models of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (APExBIO B3290). Robust quality controls (MS, NMR) and stable shipping conditions (blue ice) further support its utility in research environments.

Biological Rationale

Angiotensin converting enzyme (ACE) is a zinc metallopeptidase (EC 3.4.15.1) that catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II (Tieku & Hooper 1992). Angiotensin II plays a central role in blood pressure regulation, sodium retention, and remodeling processes in the cardiovascular and renal systems. Inhibition of ACE results in decreased angiotensin II levels, reduced aldosterone secretion, and compensatory increases in plasma renin activity. Lisinopril dihydrate is a lysine analogue of MK 421 and specifically inhibits ACE with minimal off-target effects on related peptidases such as aminopeptidase A, N, and W (Tieku & Hooper 1992, Table 1). By targeting the renin-angiotensin system, lisinopril dihydrate enables mechanistic studies in hypertension, heart failure, and diabetic nephropathy models (see molecular insights).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate functions as a competitive inhibitor of ACE, binding to the active site zinc ion and blocking substrate access. The compound’s IC50 for ACE inhibition is 4.7 nM under standard buffer conditions (pH 7.4, 25°C) (Tieku & Hooper 1992, Table 1). The dihydrate form confers improved stability and handling in aqueous solutions. By preventing the generation of angiotensin II, lisinopril dihydrate leads to vasodilation, decreased vascular resistance, and lower blood pressure. Inhibition also results in decreased aldosterone levels and increased natriuresis, contributing to reduced fluid retention. Notably, lisinopril dihydrate does not significantly inhibit aminopeptidase A (EC 3.4.11.2), aminopeptidase N (EC 3.4.11.7), or aminopeptidase W (EC 3.4.11.16) at therapeutic concentrations (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC50 of 4.7 nM at pH 7.4 and 25°C (Tieku & Hooper 1992, DOI).
• No significant inhibition of aminopeptidase A, N, or W by lisinopril at concentrations up to 10 μM (Tieku & Hooper 1992, Table 1, DOI).
• Solubility in water is ≥2.46 mg/mL with gentle warming and ultrasonic treatment (APExBIO B3290, product page).
• Purity is confirmed at ≥98% by mass spectrometry and NMR (APExBIO B3290, certificate).
• Recommended storage: desiccated at room temperature; avoid long-term storage of prepared solutions (APExBIO B3290, guidelines).

Applications, Limits & Misconceptions

Lisinopril dihydrate is a preferred tool for dissecting the renin-angiotensin system in animal, tissue, and cell-based models. Its primary applications include:

• Modeling hypertension via ACE inhibition.
• Studying heart failure mechanisms, particularly post-myocardial infarction remodeling.
• Investigating diabetic nephropathy pathogenesis and intervention.
• Probing aldosterone regulation in fluid homeostasis.

For methodological detail and troubleshooting, researchers can compare workflows in Lisinopril Dihydrate: Advanced ACE Inhibition for Hypertension Models, which this article extends by providing direct citation to primary IC50 evidence and focusing on quality control parameters.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit other zinc-dependent peptidases such as aminopeptidase A, N, or W at relevant concentrations (Tieku & Hooper 1992).
• The compound is insoluble in ethanol; use water with gentle warming and ultrasound for dissolution (APExBIO B3290).
• Long-term storage of aqueous solutions is not recommended due to potential degradation (APExBIO B3290).
• Lisinopril dihydrate is not suitable for direct clinical use; it is intended for research applications only.
• Some side effects observed with other ACE inhibitors (e.g., sulfhydryl compounds) are not attributable to lisinopril dihydrate (Tieku & Hooper 1992).

This article updates the mechanistic focus of Lisinopril Dihydrate: Advancing Translational Research by providing direct evidence for target selectivity and clarifying application boundaries.

Workflow Integration & Parameters

Lisinopril dihydrate (APExBIO B3290) is supplied as a solid (molecular weight 441.52 g/mol, chemical formula C₂₁H₃₅N₃O₇). For in vitro use, dissolve in sterile water to achieve desired stock concentrations (≥2.46 mg/mL). Use gentle warming (up to 37°C) and sonication if necessary. Aliquot and store desiccated at room temperature; avoid repeated freeze-thaw cycles and long-term storage of solutions. For in vivo studies, dosing regimens should be based on target species and endpoints, referencing validated hypertension and nephropathy models. Shipping is performed on blue ice to maintain compound integrity. The product’s high purity (≥98%) is verified by mass spectrometry and NMR, ensuring batch-to-batch consistency.

For deeper molecular rationale and integration into disease models, see Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor, which this article clarifies by providing updated stability and application limits.

Conclusion & Outlook

Lisinopril dihydrate remains a benchmark ACE inhibitor for hypertension and cardiovascular research, offering high selectivity, reproducibility, and robust quality control. Its clear target specificity and well-characterized pharmacological profile facilitate mechanistic studies in a range of preclinical models. For comprehensive technical details and ordering, visit the APExBIO Lisinopril dihydrate product page. Ongoing research will further define its role in complex disease models and may inform next-generation ACE inhibitor design.